Imeth

Methotrexate, the active ingredient in Imeth, is an antimetabolite (folate antagonist) presented as an oral tablet for oral use. It is employed to treat autoimmune disorders and certain malignancies in adult patients.

GNH USA supplies Imeth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methotrexate is an antimetabolite used in autoimmune and oncologic disease pathways.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Osteosarcoma: inhibits tumor growth by blocking DNA synthesis.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Oral ulceration or mucositis. - Fatigue or general weakness. - Elevated liver enzymes. - Decreased white blood cell count.

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infection due to bone‑marrow suppression. - Acute renal failure. - Severe cutaneous reactions such as Stevens‑Johnson syndrome. - Hematologic malignancies or aplastic anemia.

Methotrexate requires careful monitoring and specific safety measures.

- Liver monitoring: perform regular liver function tests to detect hepatotoxicity. - Hematologic monitoring: check complete blood counts frequently for bone‑marrow suppression. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Renal function: adjust dose or avoid use in patients with impaired renal clearance. - Drug interactions: review concomitant medications for potential synergistic toxicity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Methotrexate interacts with several drug classes that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: heightens risk of bone‑marrow suppression. - Live vaccines: may cause uncontrolled infection. - Penicillins (high‑dose): can raise methotrexate plasma levels.

Moderate Interactions (Monitor Closely): - Proton‑pump inhibitors: may reduce renal clearance of methotrexate. - Sulfonamide antibiotics: require close blood‑count monitoring. - Azathioprine or leflunomide: additive immunosuppression. - Warfarin: enhanced anticoagulant effect, monitor INR.